Literature DB >> 20964447

HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.

Vladimir Tolmachev1, Camilla Hofström, Jennie Malmberg, Sara Ahlgren, Seyed Jalal Hosseinimehr, Mattias Sandström, Lars Abrahmsén, Anna Orlova, Torbjörn Gräslund.   

Abstract

Affibody molecules are a class of small (ca. 7 kDa) robust scaffold proteins suitable for radionuclide molecular imaging of therapeutic targets in vivo. A hexahistidine tag at the N-terminus streamlines development of new imaging probes by enabling facile purification using immobilized metal ion affinity chromatography (IMAC), as well as convenient [⁹⁹(m)Tc(CO)₃](+)-labeling. However, previous studies in mice have demonstrated that Affibody molecules labeled by this method yield higher liver accumulation of radioactivity, compared to the same tracer lacking the hexahistidine tag and labeled by an alternative method. Two variants of the HER2-binding Affibody molecule Z(HER)₂(:)₃₄₂ were made in an attempt to create a tagged tracer that could be purified by immobilized metal affinity chromatography, yet would not result in anomalous hepatic radioactivity accumulation following labeling with [⁹⁹(m)Tc(CO)₃](+). In one construct, the hexahistidine tag was moved to the C-terminus. In the other construct, every second histidine residue in the hexahistidine tag was replaced by the more hydrophilic glutamate, resulting in a HEHEHE-tag. Both variants, denoted Z(HER)₂(:)₃₄₂-H₆ and (HE)₃-Z(HER)₂(:)₃₄₂, respectively, could be efficiently purified using IMAC and stably labeled with [⁹⁹(m)Tc(CO)₃](+) and were subsequently compared with the parental H₆-Z(HER)₂(:)₃₄₂ having an N-terminal hexahistidine tag. All three variants were demonstrated to specifically bind to HER2-expressing cells in vitro. The hepatic accumulation of radioactivity in a murine model was 2-fold lower with [⁹⁹(m)Tc(CO)₃](+)-Z(HER2:342)-H₆ compared to [⁹⁹(m)Tc(CO)₃](+)-H₆-Z(HER)₂(:)₃₄₂, and more than 10-fold lower with [⁹⁹(m)Tc(CO)₃](+)-(HE)₃-Z(HER)₂(:)₃₄₂. These differences translated into appreciably superior tumor-to-liver ratio for [⁹⁹(m)Tc(CO)₃](+)-(HE)₃-Z(HER)₂(:)₃₄₂ compared to the alternative conjugates. This information might be useful for development of other scaffold-based molecular imaging probes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20964447     DOI: 10.1021/bc1002357

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  25 in total

1.  Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.

Authors:  Hanna Lindberg; Camilla Hofström; Mohamed Altai; Hadis Honorvar; Helena Wållberg; Anna Orlova; Stefan Ståhl; Torbjörn Gräslund; Vladimir Tolmachev
Journal:  Tumour Biol       Date:  2012-01-17

2.  Site-Specific Labeling of F-18 Proteins Using a Supplemented Cell-Free Protein Synthesis System and O-2-[18F]Fluoroethyl-L-Tyrosine: [18F]FET-HER2 Affibody Molecule.

Authors:  Ai Yanai; Ryuichi Harada; Ren Iwata; Takeo Yoshikawa; Yoichi Ishikawa; Shozo Furumoto; Takanori Ishida; Kazuhiko Yanai
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

3.  Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.

Authors:  Jennie Malmberg; Anna Perols; Zohreh Varasteh; Mohamed Altai; Alexis Braun; Mattias Sandström; Ulrike Garske; Vladimir Tolmachev; Anna Orlova; Amelie Eriksson Karlström
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-30       Impact factor: 9.236

4.  Preclinical evaluation of 99mTc direct labeling ZHER2:V2 for HER2 positive tumors imaging.

Authors:  Yang Yang; Xinming Zhao; Yu Xing; Tianying Yu; Jingmian Zhang; Jianfang Wang
Journal:  Oncol Lett       Date:  2018-08-08       Impact factor: 2.967

5.  Novel, cysteine-modified chelation strategy for the incorporation of [M(I)(CO)(3)](+) (M = Re, (99m)Tc) in an α-MSH peptide.

Authors:  Han Jiang; Benjamin B Kasten; Hongguang Liu; Shibo Qi; Yang Liu; Mei Tian; Charles L Barnes; Hong Zhang; Zhen Cheng; Paul D Benny
Journal:  Bioconjug Chem       Date:  2012-11-08       Impact factor: 4.774

6.  [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.

Authors:  Anna Orlova; Camilla Hofström; Joanna Strand; Zohreh Varasteh; Mattias Sandstrom; Karl Andersson; Vladimir Tolmachev; Torbjörn Gräslund
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-21       Impact factor: 9.236

7.  Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.

Authors:  Anna Orlova; Magdalena Malm; Maria Rosestedt; Zohreh Varasteh; Ken Andersson; Ram Kumar Selvaraju; Mohamed Altai; Hadis Honarvar; Joanna Strand; Stefan Ståhl; Vladimir Tolmachev; John Löfblom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-13       Impact factor: 9.236

Review 8.  A nuclear chocolate box: the periodic table of nuclear medicine.

Authors:  Philip J Blower
Journal:  Dalton Trans       Date:  2015-03-21       Impact factor: 4.390

9.  Optimal His-Tag Design for Efficient [99mTc(CO)3]+ and [188Re(CO)3]+ Labeling of Proteins for Molecular Imaging and Radionuclide Therapy by Analysis of Peptide Arrays.

Authors:  Jennifer D Williams; Florian Kampmeier; Adam Badar; Kevin Howland; Margaret S Cooper; Gregory E D Mullen; Philip J Blower
Journal:  Bioconjug Chem       Date:  2020-11-26       Impact factor: 4.774

10.  Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain.

Authors:  Yongsheng Liu; Anzhelika Vorobyeva; Tianqi Xu; Anna Orlova; Annika Loftenius; Theresa Bengtsson; Per Jonasson; Vladimir Tolmachev; Fredrik Y Frejd
Journal:  Pharmaceutics       Date:  2021-06-07       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.